Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab

Cesare Hassan, E Ierardi, O Burattini, V De Francesco, A Zullo, G Stoppino, C Panella, S. Morini

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Treatment with the anti-tumour necrosis factor alpha monoclonal antibody infliximab has been shown to be effective in moderate-to-severe ulcerative colitis. However, its effect on the mucosal histopathological abnormalities of this disease is largely unknown. This study aimed to assess the immunohistological effect of infliximab in ulcerative colitis.
Original languageEnglish
Pages (from-to)811-817
Number of pages7
JournalDigestive and Liver Disease
Volume39
DOIs
Publication statusPublished - 2007
Externally publishedYes

Keywords

  • Adult
  • Aged
  • Antibodies, Monoclonal
  • Colitis, Ulcerative
  • Down-Regulation
  • Female
  • Humans
  • Immunologic Factors
  • Inflammation
  • Male
  • Middle Aged
  • Tumor Necrosis Factor-alpha

Fingerprint

Dive into the research topics of 'Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab'. Together they form a unique fingerprint.

Cite this